RS95904A - Tri -substituted heteroaryls and methods for making and using the same - Google Patents

Tri -substituted heteroaryls and methods for making and using the same

Info

Publication number
RS95904A
RS95904A YU95904A YUP95904A RS95904A RS 95904 A RS95904 A RS 95904A YU 95904 A YU95904 A YU 95904A YU P95904 A YUP95904 A YU P95904A RS 95904 A RS95904 A RS 95904A
Authority
RS
Serbia
Prior art keywords
tri
making
methods
same
substituted heteroaryls
Prior art date
Application number
YU95904A
Other languages
Serbian (sr)
Inventor
Wen-Cherng Lee
Lihong Sun
Feng Shan
Claudio Chuaqui
Zhongli Zheng
Russell Petter
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of RS95904A publication Critical patent/RS95904A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds of formula (I) possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders. In one embodiment, the invention features a compound of the general formula (I).
YU95904A 2002-04-04 2003-04-04 Tri -substituted heteroaryls and methods for making and using the same RS95904A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36979302P 2002-04-04 2002-04-04
PCT/US2003/010440 WO2003087304A2 (en) 2002-04-04 2003-04-04 Tri-substituted heteroaryls and methods of making and using the same

Publications (1)

Publication Number Publication Date
RS95904A true RS95904A (en) 2006-10-27

Family

ID=29250467

Family Applications (1)

Application Number Title Priority Date Filing Date
YU95904A RS95904A (en) 2002-04-04 2003-04-04 Tri -substituted heteroaryls and methods for making and using the same

Country Status (19)

Country Link
US (1) US7612094B2 (en)
EP (1) EP1499308A4 (en)
JP (1) JP2005527590A (en)
KR (1) KR20040094908A (en)
CN (1) CN100448868C (en)
AR (1) AR039241A1 (en)
AU (1) AU2003228446B2 (en)
CA (1) CA2480860A1 (en)
EA (1) EA010418B1 (en)
IL (1) IL164295A0 (en)
IS (1) IS7475A (en)
MX (1) MXPA04009546A (en)
NO (1) NO20044779L (en)
NZ (1) NZ536202A (en)
PL (1) PL373502A1 (en)
RS (1) RS95904A (en)
UA (1) UA81624C2 (en)
WO (1) WO2003087304A2 (en)
ZA (1) ZA200407902B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217787D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd C ompounds
ES2325687T3 (en) * 2002-09-18 2009-09-14 Pfizer Products Inc. NEW IMIDAZOL COMPOUNDS AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF).
AP2005003262A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel isothiazole and isoxazole compounds as tranforming growth factor (TGF) inhibitors.
PL375979A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
MXPA05002332A (en) 2002-09-18 2005-06-08 Pfizer Prod Inc Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors.
BR0314577A (en) 2002-09-18 2005-08-09 Pfizer Prod Inc Triazole derivatives as transforming growth factor (tgf) inhibitors
PA8595001A1 (en) 2003-03-04 2004-09-28 Pfizer Prod Inc NEW CONDENSED HETEROAROMATIC COMPOUNDS THAT ARE INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF)
MXPA06008157A (en) * 2003-12-24 2007-09-07 Johnson & Johnson Treatment of malignant gliomas with tgf-beta inhibitors.
AU2005219737B2 (en) * 2004-03-05 2009-11-19 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
US20080319012A1 (en) 2004-04-21 2008-12-25 In2Gen Co., Ltd. 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors
WO2006026306A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylimidazoles as tgf-beta inhibitors
US20070275968A1 (en) * 2004-09-07 2007-11-29 Hitoshi Kurata Substituted Biphenyl Derivative
AU2005289887A1 (en) 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
EP1804801A2 (en) * 2004-10-15 2007-07-11 Biogen Idec MA, Inc. Methods of treating vascular injuries
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US20100166819A1 (en) 2005-12-22 2010-07-01 Biogen Idec Ma Inc. A Corporation Transforming Growth Factor Modulators
PL2083863T3 (en) 2006-10-03 2015-08-31 Genzyme Corp Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia
WO2009009059A1 (en) * 2007-07-09 2009-01-15 Biogen Idec Ma Inc. Spiro compounds as antagonists of tgf-beta
US8138168B1 (en) 2007-09-26 2012-03-20 Takeda Pharmaceutical Company Limited Renin inhibitors
WO2009115572A2 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
CL2009000904A1 (en) * 2008-04-21 2010-04-30 Shionogi & Co Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
CN102083439A (en) * 2008-05-30 2011-06-01 萨马保健系统有限责任公司 Methods for using TGF-beta receptor inhibitors or activin-like kinase (ALK) 5 inhibitors A-83-01 and SB-431542 to treat eye disease and wound healing conditions
WO2010011917A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Llc SEH AND 11β-HSD1 DUAL INHIBITORS
WO2010121162A1 (en) * 2009-04-17 2010-10-21 Summa Health Systems Llc Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US8513222B2 (en) 2010-06-29 2013-08-20 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
USRE47141E1 (en) 2010-06-29 2018-11-27 EWHA University—Industry Collaboration Foundation Methods of treating fibrosis, cancer and vascular injuries
US8871744B2 (en) 2010-07-21 2014-10-28 B & G Partyers, LLC Compounds and methods for selectively targeting tumor-associated mucins
PT2731949T (en) 2011-07-13 2018-06-15 Tiumbio Co Ltd 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
US20140308275A1 (en) 2011-07-27 2014-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods for diagnosing and treating myhre syndrome
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN105308033B (en) 2013-03-14 2018-08-24 特雷罗药物股份有限公司 JAK2 and ALK2 inhibitor and its application method
JP6723930B2 (en) 2014-02-07 2020-07-15 エムティーエー タモガトット クタトクソポルトク イロダジャ Novel use of sigma-1-receptor agonist compounds
US10842794B2 (en) 2014-02-07 2020-11-24 Támogatott Kutatócsoportok Irodája Use of Sigma-1 receptor agonist compounds
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
MX2019003095A (en) 2016-09-19 2019-07-04 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor.
PT3618875T (en) 2017-05-02 2023-08-07 Novartis Ag Combination therapy
EP3774798A1 (en) * 2018-04-02 2021-02-17 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
CN112512597A (en) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 Methods for treating diseases associated with aberrant ACVR1 expression and ACVR1 inhibitors useful therefor
JP7335344B2 (en) * 2019-01-22 2023-08-29 ビシケム カンパニー リミテッド Fused ring heteroaryl compounds as ALK4/5 inhibitors
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
JP2023509760A (en) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド ALK5 inhibitor complexes and uses thereof
KR20230051500A (en) 2020-07-15 2023-04-18 키에시 파르마슈티시 엣스. 피. 에이. Pyridazinyl amino derivatives as ALK5 inhibitors
JP2023533850A (en) 2020-07-15 2023-08-04 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Pyridoxazine amino derivatives as ALK5 inhibitors
WO2022013311A1 (en) 2020-07-15 2022-01-20 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
US20240116948A1 (en) 2020-12-23 2024-04-11 Chiesi Farmaceutici S.P.A. Pyrido oxazine derivatives as alk5 inhibitors
CN112759592A (en) * 2021-02-01 2021-05-07 无锡鸣鹭医药科技有限公司 Synthetic method of 6-iodo [1,2,3] triazolo [1,5-a ] pyridine
CN114105975A (en) * 2021-02-25 2022-03-01 无锡海伦生物科技有限公司 Synthetic method of [1,2,4] triazole [1,5-A ] pyridine-6-formaldehyde
AR127108A1 (en) 2021-09-21 2023-12-20 Chiesi Farm Spa PYRDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS
WO2023208986A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Imidazole derivatives as alk5 inhibitors
WO2024111626A1 (en) * 2022-11-25 2024-05-30 カルナバイオサイエンス株式会社 Novel thiazole derivative

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4302464A (en) 1980-10-16 1981-11-24 Pfizer Inc. Imidazolylpyridine therapeutic agents
IL101291A0 (en) * 1991-03-22 1992-11-15 Nippon Soda Co 2-pyridine derivatives,their preparation and their use as fungicides
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
DK64592D0 (en) * 1992-05-14 1992-05-14 Carlbiotech Ltd As PEPTIDES FOR THERAPEUTIC TREATMENT
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
GB9423460D0 (en) 1994-11-21 1995-01-11 Merck Sharp & Dohme Therapeutic agents
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp Imidazole derivatives, process for their preparation and pharmaceutical compositions comprising them
US6369068B1 (en) 1995-06-07 2002-04-09 Smithkline Beecham Corporation Amino substituted pyrimidine containing compounds
US5854276A (en) 1995-06-29 1998-12-29 Fujisawa Pharmaceutical Co., Ltd. Substance WF16616, process for production thereof, and use thereof
US5837719A (en) 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5792778A (en) 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6083949A (en) 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
CZ216498A3 (en) 1996-01-11 1999-08-11 Smithkline Beecham Corporation Novel substituted imidazole compounds
JP2000504013A (en) 1996-02-01 2000-04-04 スミスクライン・ビーチャム・コーポレイション Endothelin receptor antagonist
JP2000507224A (en) 1996-03-08 2000-06-13 スミスクライン・ビーチャム・コーポレイション Use of CSAID compounds as inhibitors of angiogenesis
EP0888335A4 (en) 1996-03-13 2002-01-02 Smithkline Beecham Corp Novel pyrimidine compounds useful in treating cytokine mediated diseases
JP2000507545A (en) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Novel treatment for CNS injury
EP0889888A4 (en) 1996-03-25 2003-01-08 Smithkline Beecham Corp Novel treatment for cns injuries
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5872136A (en) 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5939557A (en) 1996-04-03 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5854265A (en) 1996-04-03 1998-12-29 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
AU708883B2 (en) 1996-06-10 1999-08-12 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US5854264A (en) 1996-07-24 1998-12-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
KR20000057137A (en) 1996-11-19 2000-09-15 스티븐 엠. 오드레 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1028954B1 (en) 1997-04-24 2003-07-02 Ortho-McNeil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory diseases
RU2249591C2 (en) 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3-(5)-heteroaryl-substituted pyrazoles as kinase p38 inhibitors
US6087496A (en) * 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CN100443481C (en) * 1997-06-12 2008-12-17 艾文蒂斯药品有限公司 Imidazolyl-cyclic acetals
WO1998056377A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
JP2002515915A (en) 1997-06-30 2002-05-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 2-Substituted imidazoles useful in treating inflammatory diseases
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
EP1037639A4 (en) 1997-12-19 2002-04-17 Smithkline Beecham Corp Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
WO2000010563A1 (en) 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
JP2002528506A (en) 1998-11-04 2002-09-03 スミスクライン・ビーチャム・コーポレイション Pyridin-4-yl or pyrimidin-4-yl substituted pyrazine
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
US6288089B1 (en) 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
JP4632544B2 (en) 1998-12-25 2011-02-16 あすか製薬株式会社 Aminopyrazole derivatives
EP1175419B1 (en) 1999-04-02 2003-05-28 Bristol-Myers Squibb Pharma Company Aryl sulfonyls as factor xa inhibitors
DE60001229T2 (en) * 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia triarylimidazoles
CO5170501A1 (en) 1999-04-14 2002-06-27 Novartis Ag USEFUL REPLACED BLUES FOR THE TREATMENT OF DISEASES MEDIATED BY TNFa eIL-1 AND DISEASES OF THE OSEO METABOLISM
US6667325B1 (en) * 1999-06-03 2003-12-23 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
EP1196167B1 (en) * 1999-07-02 2006-04-19 Stuart A. Lipton Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions
US20030109428A1 (en) * 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
JP2003518123A (en) * 1999-12-21 2003-06-03 スージェン・インコーポレーテッド 4-Substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
WO2001091749A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
EP1296977A1 (en) 2000-06-23 2003-04-02 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
CN1471523A (en) * 2000-09-21 2004-01-28 ʷ Imidazole derivatives as Raf kinase inhibitors
US6755497B2 (en) * 2000-09-26 2004-06-29 Canon Kabushiki Kaisha Ink-jet printing apparatus, control method thereof, and data processing apparatus and method
JP2002114780A (en) * 2000-10-11 2002-04-16 Taisho Pharmaceut Co Ltd 4-(3-indolyl)imidazole derivative
US6630325B1 (en) * 2000-10-19 2003-10-07 Maine Medical Center Research Institute Compositions, methods and kits relating to remodel
WO2002040468A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Compounds
AU2002236476A1 (en) * 2000-11-20 2002-05-27 Smith Kline Beecham Corporation Novel compounds
GB0100762D0 (en) * 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
US20040097502A1 (en) * 2001-02-02 2004-05-20 Gellibert Francoise Jeanne Pyrazoles as tgf inhibitors
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
EP1355903B1 (en) * 2001-02-02 2005-03-16 SmithKline Beecham Corporation Pyrazole derivatives against tgf overexpression
GB0102665D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
AU2002345603B2 (en) * 2001-06-07 2006-10-12 Skinmedica, Inc. Conditioned cell culture media and uses thereof
US7300442B2 (en) * 2001-07-11 2007-11-27 Daniel Cherfas Method of destroying formations in a body
WO2003097615A1 (en) * 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
ES2325687T3 (en) * 2002-09-18 2009-09-14 Pfizer Products Inc. NEW IMIDAZOL COMPOUNDS AS INHIBITORS OF THE TRANSFORMING GROWTH FACTOR (TGF).
MXPA05002332A (en) * 2002-09-18 2005-06-08 Pfizer Prod Inc Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors.

Also Published As

Publication number Publication date
EA010418B1 (en) 2008-08-29
CN1658866A (en) 2005-08-24
KR20040094908A (en) 2004-11-10
EP1499308A4 (en) 2006-05-24
UA81624C2 (en) 2008-01-25
AR039241A1 (en) 2005-02-16
WO2003087304A3 (en) 2004-07-22
NZ536202A (en) 2009-08-28
US7612094B2 (en) 2009-11-03
CN100448868C (en) 2009-01-07
IL164295A0 (en) 2005-12-18
EP1499308A2 (en) 2005-01-26
IS7475A (en) 2004-09-28
AU2003228446A1 (en) 2003-10-27
WO2003087304A2 (en) 2003-10-23
PL373502A1 (en) 2005-09-05
ZA200407902B (en) 2005-09-22
JP2005527590A (en) 2005-09-15
NO20044779L (en) 2005-01-04
CA2480860A1 (en) 2003-10-23
EA200401309A1 (en) 2005-08-25
AU2003228446B2 (en) 2009-08-06
MXPA04009546A (en) 2005-01-25
US20060063809A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
RS95904A (en) Tri -substituted heteroaryls and methods for making and using the same
RS20050199A (en) Imidazolopyridines and methods of making and using the same
RS20050616A (en) Pyrazoles and methods of making and using the same
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
RS20050200A (en) Pyrazolopyridines and methods of making and using the same
TW200621752A (en) Pyrimidinylpyrazoles and methods of making and using the same
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
HK1083838A1 (en) A2a adenosine receptor antagonists
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
JO2311B1 (en) Alkyne-aryl phosphodiesterase-4 inhibitors
IL163911A0 (en) Naltrexone hydrochloride compositions
GB0325956D0 (en) Novel compounds
IL159418A0 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
MY135841A (en) Novel benzodioxoles
DE60324544D1 (en) MUSCARIN ANTAGONISTS
BG101110A (en) Substituted pyrimidine compounds and their application
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
CA2443285A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
MXPA04004477A (en) Nk1 antagonists.
BRPI0414678A (en) polymorphic form of 3-phenyl sulfonyl-8-piperazin-1-yl quinoline
MXPA04005988A (en) 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives.
MXPA04004980A (en) Ccr-3 receptor antagonists vii.
HU0201195D0 (en)
MXPA03010325A (en) Substituted benzoylcyclohexenones and their use as herbicidal agents.